Advancing Rationally-Designed Microbial Consortia for Ulcerative Colitis and Beyond
10:00 am - Wednesday 28th January 2026
- Presenting Phase 2b development of MH002 for ulcerative colitis and insights from earlier clinical trials
- Assessing MH002’s mode-of-action and highlighting the CORAL platform’s role in designing potent and scalable LBPs
- Exploring and future applications in pouchitis and immune-oncology through strategic partnerships and pipeline expansion
